All In MedTech

FDA Clearance Tracker · P150013-S021

PD-L1 IHC 22C3 pharmDx

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Feb 22, 2021 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Feb 22, 2021

Approved

Time to decision

175 days

Received Aug 31, 2020. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P150013-S021
Device name
PD-L1 IHC 22C3 pharmDx
Applicant location
Santa Clara, CA
Received
Aug 31, 2020
Decided
Feb 22, 2021
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P150013

Device type

Device class
Class III

Every decision under product code PLS

FDA's approval statement

As written in FDA's record.

Approval for the PD-L1 IHC 22C3 pharmDX as a companion diagnostic device to detect PD-L1 protein (Tumor Proportion Score ?50%) in patients with non-small cell lung cancer (NSCLC) for treatment with LIBTAYO.

Source documents

Other decisions for Agilent Technologies, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.